Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers

Biochemical Pharmacology

Volumn 54, Issue 11, 1997, Pages 1195-1203

  Yamazaki, Hiroshi ^a   Shimada, Tsutomu ^a  

^a OSAKA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

CYP1A2; CYP2C9; Drug interaction; Inhibition; R warfarin; S warfarin

Indexed keywords

CYTOCHROME P450; ISOENZYME; MEPHENYTOIN; SULFAPHENAZOLE; TOLBUTAMIDE; WARFARIN;

ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG METABOLISM; ENANTIOMER; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; HYDROXYLATION; IN VITRO STUDY; LIVER MICROSOME; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTICOAGULANTS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYDROXYLATION; MALE; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; SULFAPHENAZOLE; TOLBUTAMIDE; WARFARIN;

EID: 0030700392     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00304-3     Document Type: Article

References (59)

1. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC and Nebert DW, P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6: 1-42, 1996.
2. Gonzalez FJ, The molecular biology of cytochrome P450s. Pharmacol Rev 40: 243-288, 1989.
3. Guengerich FP, Reactions and significance of cytochrome P-450 enzymes. J Biol Chem 266: 10019-10022, 1991.
4. Goldstein JA and de Morais SMF, Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4: 285-299, 1994.
5. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423, 1994.
6. Romkes M, Faletto MB, Blaisdell JA, Raucy JL and Goldstein JA, Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 30: 3247-3255, 1991.
7. Kaminsky LS and Zhang Z-Y, Human P450 metabolism of warfarin. Pharmacol Ther 73: 67-74, 1997.
8. Kaminsky LS, Dunbar DA, Wang PP, Beaune P, Larry D, Guengerich FP, Schnellmann RG and Sipes IG, Human hepatic cytochrome P-450 composition as probed by in vitro microsomal metabolism of warfarin. J Pharmacol Exp Ther 12: 470-477, 1984.
9. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ and Trager WF, Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin - drug interactions. Chem Res Toxicol 5: 54-59, 1992.
10. Kaminsky LS, de Morais SMF, Faletto MB, Dunbar DA and Goldstein JA, Correlation of human cytochrome P4502C substrate specificities with primary structure: Warfarin as a probe. Mol Pharmacol 43: 234-239, 1993.
11. Wang PP, Beaune P, Kaminsky LS, Dannan GA, Kadlubar FF, Larrey D and Guengerich FP, Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. Biochemistry 22: 5375-5383, 1983.
12. Hermans J and Thijssen H, Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br J Clin Pharmacol 110: 482-490, 1993.
13. Zhang Z, Fasco MJ, Huang Z, Guengerich FP and Kaminsky LS, Human cytochromes P4501A1 and P4501A2: R-Warfarin metabolism as a probe. Drug Metab Dispos 23: 1339-1345, 1995.
14. Kivistö KT, Neuvonen PJ and Klotz U, Inhibition of terfenadine metabolism. Clin Pharmacokinet 27: 1-5, 1994.
15. Skett P, Tyson C, Guillouzo A and Maier P, Report on the international workshop on the use of human in vitro liver preparations to study drug metabolism in drug development. Biochem Pharmacol 50: 280-285, 1995.
16. Wrighton SA, Ring BJ and Vandenbranden M, The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies. Toxicol Pathol 23: 199-208, 1995.
17. Birkett DJ, Mackenzie PI, Veronese ME and Miners JO, In vitro approaches can predict human drug metabolism. Trends Pharmacol Sci 14: 292-294, 1993.
18. Spatzenegger M and Jaeger W, Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 27: 397-417, 1995.
19. Grind M, Murphy M, Warrington S and Aberg J, Method for studying drug-warfarin interactions. Clin Pharmacol Ther 54: 381-387, 1993.
20. Brian WR, Srivastava PK, Umbenhauer DR, Lloyd RS and Guengerich FP, Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 28: 4993-4999, 1989.
21. TB (CYP2C9) by (±)-fluvastatin. Clin Pharmacol Ther 58: 412-417, 1995.
22. Kunze KL and Trager WF, Warfarin-fluconazole. III. A rational approach to management of a metabolically based drug interaction. Drug Metab Dispos 24: 429-435, 1996.
23. Mancy A, Dijols S, Poli S, Guengerich FP and Mansuy D, Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: Molecular origin of the specific inhibitory effects of sulfaphenazole on CYP2C9 and consequences for the substrate binding site topology of CYP2C9. Biochemistry 35: 16205-16212, 1996.
24. Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP and Shimada T, Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 7: 103-113, 1997.
25. Yamazaki H, Inoue K, Turvy CG, Guengerich FP and Shimada T, Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes. Drug Metab Dispos 25: 168-174, 1997.
26. Guengerich FP, Analysis and characterization of enzymes. In: Principles and Methods of Toxicology (Ed. Hayes AW), pp. 1259-1313. Raven Press, New York, 1994.
27. Guo Z, Gillam E, Ohmori S, Tukey RH and Guengerich FP, Expression of modified human cytochrome P450 1A1 in Escherichia coli: Effects of 5′ substitution, stabilization, purification, spectral characterization, and catalytic properties. Arch Biochem Biophys 312: 436-446, 1994.
28. Sandhu P, Guo Z, Baba T, Martin MV, Tukey RH and Guengerich FP, Expression of modified human cytochrome P450 1A2 in Escherichia coli. Stabilization, purification, spectral characterization, and catalytic activities of the enzymes. Arch Biochem Biophys 309: 168-177, 1994.
29. Sandhu P, Baba T and Guengerich FP, Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity. Arch Biochem Biophys 306: 443-450, 1993.
30. Gillam EMJ, Guo Z and Guengerich FP, Expression of modified human cytochrome P450 2E1 in Escherichia coli, purification, and spectral and catalytic properties. Arch Biochem Biophys 312: 59-66, 1994.
31. Gillam E, Baba T, Kim BR, Ohmori S and Guengerich FP, Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch Biochem Biophys 305: 123-131, 1993.
32. Shimada T, Misono KS and Guengerich FP, Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. J Biol Chem 261: 909-921, 1986.
33. Yasukochi Y and Masters B, Some properties of a detergent-solubilized NADPH-cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography. J Biol Chem 251: 5337-5344, 1976.
34. Taniguchi H, Imai Y, Iyanagi T and Sato R, Interaction between NADPH-cytochrome P-450 reductase and cytochrome P-450 in the membrane of phosphatidylcholine vesicles. Biochim Biophys Acta 550: 341-356, 1979.
35. Kaminsky LS, Fasco MJ and Guengerich FP, Production and application of antibodies to rat liver cytochrome P-450. Methods Enzymol 74: 262-272, 1981.
36. Distlerath LM, Reilly P, Martin MV, Davis GG, Wilkinson GR and Guengerich FP, Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 260: 9057-9067, 1985.
37. Knodell RG, Hall SD, Wilkinson GR and Guengerich FP, Hepatic metabolism of tolbutamide: Characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J Pharmacol Exp Ther 241: 1112-1119, 1987.
38. 5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Arch Biochem Biophys 325: 174-182, 1996.
39. Srivastava PK, Yun CH, Beaune PH, Ged C and Guengerich FP, Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol Pharmacol 40: 69-79, 1991.
40. Lang D and Böcker R, Highly sensitive and specific high-performance liquid chromatographic analysis of 7-hydroxy-warfarin, a marker for human cytochrome P-4502C9 activity. J Chromatogr B Biomed Appl 672: 305-309, 1995.
41. Pohl RJ and Fouts JR, A rapid method for assaying the metabolism of 7-ethoxyresorufin by microsomal subcellular fractions. Anal Biockem 107: 150-155, 1980.
42. Omura T and Sato R, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239: 2370-2378, 1964.
43. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ, Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
44. Halpert JR, Guengerich FP, Bend JR and Correia MA, Selective inhibitors of cytochromes P450. Toxicol Appl Pharmacol 125: 163-175, 1994.
45. Yamazaki H, Urano T, Hiroki S and Shimada T, Effects of erythromycin and roxithromycin on oxidation of testosterone and nifedipine catalyzed by CYP3A4 in human liver microsomes. J Toxicol Sci 21: 215-226, 1996.
46. Abernethy DR, Kaminsky LS and Dickinson TH, Selective inhibition of warfarin metabolism by diltiazem in humans. J Pharmacol Exp Ther 257: 411-415, 1991.
47. Watkins PB, Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4: 171-184, 1994.
48. Kunze KL, Wienkers LC, Thummel KE and Trager WF, Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: In vitro studies. Drug Metab Dispos 24: 414-421, 1996.
49. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC and Cantilena LR, Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269: 1513-1518, 1993.
50. Jurima-Romet M, Crawford K, Cyr T and Inaba T, Terfenadine metabolism in human liver in vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 22: 849-857, 1994.
51. Newton DJ, Wang RW and Lu AYH, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23: 154-158, 1995.
52. Murray M and Reidy GF, Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol Rev 42: 85-101, 1990.
53. Guengerich FP and Shimada T, Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 4: 391-407, 1991.
54. Yamazaki H, Inui Y, Yun CH, Guengerich FP and Shimada T, Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13: 1789-1794, 1992.
55. Kunze KL, Eddy AC, Gibaldi M and Trager WF, Metabolic enantiotneric interactions: The inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin. Chirality 3: 24-29, 1991.
56. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE and Loft S, Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45: 1211-1214, 1993.
57. Rasmussen BB, Mäenpää J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J and Brøsen K, Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine. Br J Clin Pharmacol 39: 151-159, 1995.
58. Jensen KG, Poulsen HE, Doehmer J and Loft S, Kinetics and inhibition by fluvoxamine of phenacetin O-deethylation in V79 cells expressing human CYP1A2. Pharmacol Toxicol 76: 286-288, 1995.
59. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE and Brøsen K, Dose-dependent inhibition of CYP1A2, CYP2C19, and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur Clin Pharmocol 51: 73-78, 1996.